WE ARE CHARTING A NEW COURSE TO COMPREHENSIVELY DRUG THE HUMAN IMMUNE SYSTEM

We’re building Compass with a singular goal in mind: unlocking the complexity of the immune system. Our discovery and development teams work together to fully characterize and evaluate novel antibodies and rapidly generate therapeutic candidates. We are leveraging those insights to develop transformational therapies for cancer, inflammation and autoimmune diseases.
WE ARE BUILDING A UNIQUE PIPELINE THAT EMBRACES THE UNEXPECTED
Conventional drug discovery often focuses on a narrow set of targets and mechanisms. At Compass, we generate therapeutic candidates – both agonists and antagonists -- that engage with a wide range of epitopes on every target. Our proprietary technology lets us conduct methodical, unbiased analyses of these candidates and uncover epitope-related biology and unexpected synergies. The result: A robust pipeline of next-generation monotherapies, drug combinations and multispecifics in cancer, inflammation, and autoimmune diseases.

WE ARE MOVING RAPIDLY TOWARD THE CLINIC

Backed by $132 million in Series A financing, we are committed to building a fully integrated biopharma company that will lead the way in modulating the human immune system to treat diseases. Our team is defined by commitment to patients, integrity, tenacity and a passion for unlocking the complexity of the human immune system.